News & Events
SEATTLE, September 3, 2019 — Impel NeuroPharma today announced the last patient has been enrolled in “STOP-301” (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute…
SEATTLE, July 10, 2019 — Previously Reported STOP 101 Data, Including New Analysis Evaluating Cardiovascular Effects of Dihydroergotamine Mesylate (DHE) Delivered by Impel’s POD® Device, Support Bioavailability, Safety and Tolerability Profile of INP104 for Acute Migraine. Company’s Phase 3 Clinical…
SEATTLE, June 26, 2019 — Impel NeuroPharma today announced the appointment of John Leaman, M.D., as the Company’s Chief Financial Officer.